SCHEMBL4314874

SCHEMBL4314874

COc1ccc2c(n1)NCC(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.47
BIRC2 Q13490 1/20 0.47
KMT2A Q03164 2/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
DDB1 Q16531 2/20 0.40
CRBN Q96SW2 2/20 0.40
CYP11B1 P15538 3/20 0.38
CYP11B2 P19099 3/20 0.38
PDE3B Q13370 2/20 0.36
PDE3A Q14432 2/20 0.36
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
BTK Q06187 1/20 0.35
ALOX5 P09917 1/20 0.35
OPRL1 P41146 2/20 0.34
BRD4 O60885 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336059 0.87 DDB1 (0.40) XIAPBIRC2KMT2ANPC1MEN1
SCHEMBL12680350 0.78 XIAP (0.50) XIAPBIRC2KMT2ANPC1MAPT
SCHEMBL28938891 0.77 XIAP (0.50) XIAPBIRC2CYP11B1CYP11B2PDE3B
SCHEMBL13731155 0.76 MEN1 (0.37) XIAPBIRC2KMT2ANPC1MEN1
SCHEMBL16563723 0.75 XIAP (0.47) XIAPBIRC2KMT2ARAB9ACYP11B1
SCHEMBL12942010 0.74 CRBN (0.34) XIAPBIRC2DDB1CRBNCYP11B1
SCHEMBL6073595 0.73 PDE3B (0.44) KMT2ANPC1MEN1HSP90AA1MAPT
SCHEMBL6073418 0.72 CRBN (0.43) KMT2ANPC1MEN1HSP90AA1MAPT
SCHEMBL9110424 0.71 MEN1 (0.38) KMT2ANPC1MEN1HSP90AA1MAPT
SCHEMBL16563635 0.71 XIAP (0.44) XIAPBIRC2DDB1CRBNCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017508-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-07-10 US disclosed
EP-2848618-B1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-03-14 EP disclosed
US-20170129887-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2017-05-11 US disclosed
US-9469637-B2 Nitrogenated heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-10-18 US disclosed
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 US disclosed
EP-2848618-A1 NITROGENATED HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-03-18 EP disclosed
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105373-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A XIAP 3111/4885BIRC2 2042/4885KMT2A 262/4885
US-20170129887-A1 NITROGENATED HETEROCYCLIC COMPOUND PDE2A, PDE5A, PDE3A XIAP 3111/4885BIRC2 2042/4885KMT2A 262/4885
US-10017508-B2 Nitrogenated heterocyclic compound PDE2A, PDE5A, PDE3A XIAP 3111/4885BIRC2 2042/4885KMT2A 262/4885
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 XIAP 1206/4885BIRC2 1031/4885KMT2A 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.